Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer

Eitemau Tebyg

• A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada
  gan: Hirsh, V., et al.
  Cyhoeddwyd: (2012)
• ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
  gan: D. D. SAKAEVA
  Cyhoeddwyd: (2017-06-01)
• Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
  gan: Daisy Wai-Ka Chan, et al.
  Cyhoeddwyd: (2022-04-01)
• Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
  gan: Califano, R., et al.
  Cyhoeddwyd: (2015)
• Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
  gan: Wang, Jun, et al.
  Cyhoeddwyd: (2016)